This first-line protocol applies when allergic rhinitis symptoms are both mild and intermittent — meaning they occur infrequently and do not interfere with daily quality of life.
Allergic rhinitis is classified by frequency and severity. Intermittent refers to symptoms occurring four days per week or fewer, or four weeks per year or fewer. Mild means symptoms do not interfere with quality of life, sleep, sports participation, or school and work performance. This distinction directly determines which treatment approach is appropriate.
The approach centres on allergen avoidance and patient education, combined with a specific class of antihistamine used on an as-needed basis. The complete regimen — including agent selection, route, and full sequencing — is available in the structured protocol below.
The target is relief of histamine-mediated allergic rhinitis symptoms: sneezing, nasal pruritus, and rhinorrhea.
Frequency can be divided into intermittent or persistent (more than four days per week and more than four weeks per year, respectively).
Severity can be divided into mild (symptoms do not interfere with quality of life) or severe (symptoms impact asthma control, sleep, sports participation, or school or work performance).
The International Primary Care Respiratory Group; British Society for Allergy and Clinical Immunology; and American Academy of Allergy, Asthma, and Immunology recommend intranasal corticosteroids alone for the initial treatment of persistent symptoms affecting quality of life and second-generation nonsedating antihistamines for mild intermittent disease.
In general, oral antihistamines have been shown to effectively relieve the histamine-mediated symptoms associated with allergic rhinitis (e.g., sneezing, pruritus, rhinorrhea), but they are less effective than intranasal corticosteroids at treating nasal congestion and ocular symptoms.
View source ↗